Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1299-1311

  Othman, Ahmed A ^a,b   Haig, George ^a   Florian, Hana ^a   Locke, Charles ^a   Zhang, Jun ^a   Dutta, Sandeep ^a  

^a ABBOTT LABORATORIES   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

ABT 288; Alzheimer's; Cognition; H3 receptors; Pharmacokinetics; Tolerability

Indexed keywords

ABT 288; PLACEBO;

ABNORMAL DREAMING; ADULT; AGED; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE;

ADMINISTRATION, ORAL; ADULT; AGED; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HISTAMINE H3 ANTAGONISTS; HUMANS; MALE; PYRIDAZINES; PYRROLES; YOUNG ADULT;

EID: 84876019747     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04472.x     Document Type: Article

References (24)

1. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: an update. Curr Opin Psychiatry 2007; 20: 380-385.
2. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
3. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115.
4. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. In: NICE Technology Appraisal Guidance 217 (issue date March 2011). Available at http://www.nice.org.uk/guidance/TA217 (last accessed 30 October 2012).
5. Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995; 66: 413-463.
6. Hough LB. Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001; 59: 415-419.
7. Bakker RA, Timmerman H, Leurs R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 2002; 17: 27-64.
8. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001; 63: 637-672.
9. Martinez-Mir MI, Pollard H, Moreau J, Arrang JM, Ruat M, Traiffort E, Schwartz JC, Palacios JM. Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 1990; 526: 322-327.
10. Drutel G, Peitsaro N, Karlstedt K, Wieland K, Smit MJ, Timmerman H, Panula P, Leurs R. Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol 2001; 59: 1-8.
11. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999; 55: 1101-1107.
12. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302: 832-837.
13. Blandina P, Bacciottini L, Giovannini MG, Mannaioni PF. H3 receptor modulation of the release of neurotransmitters in vivo. In: Pharmacochemistry Library, eds Rob L, Henk T Amsterdam: Elsevier, 1998; 27-40.
14. Hancock AA, Fox GB. Perspectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin Investig Drugs 2004; 13: 1237-1248.
15. Witkin JM, Nelson DL. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004; 103: 1-20.
16. 3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008; 154: 1166-1181.
17. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011; 336: 38-46.
18. Bitner RS, Markosyan S, Nikkel AL, Brioni JD. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease. Neuropharmacology 2011; 60: 460-466.
19. Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD. Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2012; 343: 233-245.
20. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008; 30: 74-83.
21. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011; 163: 713-721.
22. Inocente CD, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimão R, Lin JS, Franco P. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012; 35: 55-60.
23. Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 2012; 26: 421-434.
24. Iannone R, Renger J, Potter W, Dijk D, Boyle J, Palcza J, Zhao B, Bergman A, Van Laere K, Bormans G, Sanabria S, Calder N, De Lepeleire I, Van Hoydonck P, Marsilio S, Cerchio K, Declercq R, Fox-Bosetti S, Verma A, Van Bortel L, Achten E, Ma J, Hargreaves R, Koblan K, Chodakewitz J, Gottesdiener K, Murphy G. The relationship between brain receptor occupancy (RO) and alerting effects in humans support MK-0249 and MK-3134 as inverse agonists at the histamine subtype-3 pre-synaptic receptor (H3R). American College Neuropsychopharmacology 48th Annual Meeting (acnp), Hollywood, FL, 2009 Dec 6-10; 198 (abstract).